{"disease":{"id":"b-nhl","name":"b nhl"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03869619","title":"REal World Data in LYmphoma and Survival in Adults","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03888105","title":"A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":515,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT04923048","title":"A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":460,"lead_sponsor_name":"Genor Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT01994382","title":"Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02253992","title":"An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":232,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT06230224","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":216,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT02790515","title":"Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":170,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT06695013","title":"Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT02315612","title":"Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04002947","title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05442515","title":"CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07161713","title":"SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Barbara Nemesure","has_results":false},{"nct_id":"NCT03245905","title":"Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05685173","title":"A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":91,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT06911710","title":"The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT03985696","title":"Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas","phase":"NA","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"University Hospital, Limoges","has_results":false},{"nct_id":"NCT05665530","title":"A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT04553393","title":"Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT00566696","title":"Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true},{"nct_id":"NCT03849651","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":69,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true},{"nct_id":"NCT05397496","title":"Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03980379","title":"Pharmacokinetics, Efficacy and Safety of the 304 Injection","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT06470438","title":"A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":58,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02875548","title":"A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Epizyme, Inc.","has_results":false},{"nct_id":"NCT03448393","title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05615636","title":"A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04644016","title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":31,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05869279","title":"Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":29,"lead_sponsor_name":"Fondazione Matilde Tettamanti Menotti De Marchi Onlus","has_results":false},{"nct_id":"NCT07205315","title":"A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Grit Biotechnology","has_results":false},{"nct_id":"NCT05583149","title":"Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Patrick C. Johnson, MD","has_results":true},{"nct_id":"NCT07345741","title":"Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Donghua Zhang","has_results":false},{"nct_id":"NCT05020015","title":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":27,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT06343311","title":"T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"Estrella Biopharma, Inc.","has_results":false},{"nct_id":"NCT06689917","title":"JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07059741","title":"Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT06678282","title":"JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Shenzhen Genocury Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT03229876","title":"Safety and Efficacy Evaluation of CD19-UCART","phase":"NA","overall_status":"SUSPENDED","enrollment_count":20,"lead_sponsor_name":"Bioray Laboratories","has_results":false},{"nct_id":"NCT07334574","title":"Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT04933825","title":"A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"EdiGene (GuangZhou) Inc.","has_results":false},{"nct_id":"NCT06279611","title":"An Evaluation of LY007 Cell Injection for r/r B-NHL","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Shanghai Longyao Biotechnology Inc., Ltd.","has_results":false},{"nct_id":"NCT06364852","title":"An Evaluation of LY007 Cell Injection for r/r B-NHL","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05535673","title":"Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Zhengzhou University","has_results":false},{"nct_id":"NCT07478848","title":"Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":14,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":false},{"nct_id":"NCT06693973","title":"An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":13,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05513612","title":"Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Shanghai Pudong Hospital","has_results":false},{"nct_id":"NCT05619367","title":"A Compassionate Use (CU) Program of Odronextamab","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":46},"guidelines":[],"source":"Drug Landscape verified database"}